Page |
||||
F-2 |
||||
F-3 |
||||
F-5 |
||||
F-6 |
||||
F-8 |
||||
F-10 |
As of December 31, |
||||||||
2020 |
2019 |
|||||||
Assets |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | $ | ||||||
Accounts receivable, net |
||||||||
Accounts receivable, net from related parties (Note 2 0 ) |
||||||||
Inventory, net |
||||||||
Prepaid expenses and other current assets |
||||||||
|
|
|
|
|||||
Total current assets |
||||||||
Property and equipment, net |
||||||||
Investments |
||||||||
Equity method investments |
||||||||
Intangible assets, net |
||||||||
Goodwill |
||||||||
Loans receivable, net of current portion |
||||||||
Other non-current assets |
||||||||
|
|
|
|
|||||
Total assets |
$ | $ | ||||||
|
|
|
|
|||||
Liabilities and Stockholders’ Equity |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | $ | ||||||
Accrued expenses and other current liabilities |
||||||||
Deferred revenue (includes $ |
||||||||
|
|
|
|
|||||
Total current liabilities |
||||||||
Non-current liabilities: |
||||||||
Deferred rent, net of current portion |
||||||||
Deferred revenue, net of current portion (includes $ |
||||||||
Lease financing obligation |
||||||||
Other non-current liabilities |
||||||||
|
|
|
|
|||||
Total liabilities |
||||||||
|
|
|
|
|||||
Commitments and contingencies (Note 11) |
||||||||
Stockholders’ equity (1) : |
||||||||
Preferred stock , $shares authorized; |
(1) |
Retroactively restated for the reverse recapitalization as described in Note 1. |
As of December 31, |
||||||||
2020 |
2019 |
|||||||
Class A, Class B and Class C common stock $shares authorized , Class B , Class C ); (Class A |
$ |
$ |
||||||
Additional paid in capital |
||||||||
Accumulated deficit |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total Ginkgo Bioworks, Inc. stockholders’ equity |
||||||||
Non-controlling interest |
||||||||
|
|
|
|
|||||
Total stockholders’ equity |
||||||||
|
|
|
|
|||||
Total liabilities and stockholders’ equity |
$ | $ | ||||||
|
|
|
|
Year Ended December 31, |
||||||||
2020 |
2019 |
|||||||
Foundry revenue (includes related party revenue of $ |
$ | $ | ||||||
Biosecurity revenue: |
||||||||
Product |
— | |||||||
Service |
— | |||||||
|
|
|
|
|||||
Total revenue |
||||||||
|
|
|
|
|||||
Costs and operating expenses: |
||||||||
Cost of Biosecurity product revenue |
— | |||||||
Cost of Biosecurity service revenue |
— | |||||||
Research and development |
||||||||
General and administrative |
||||||||
|
|
|
|
|||||
Total operating expenses |
||||||||
|
|
|
|
|||||
Loss from operations |
( |
) | ( |
) | ||||
Other income (expense), net: |
||||||||
Interest income |
||||||||
Interest expense |
( |
) | ( |
) | ||||
Loss on equity method investments |
( |
) | ( |
) | ||||
Loss on investments |
( |
) | ( |
) | ||||
Other income, net (includes $ |
||||||||
|
|
|
|
|||||
Total other income (expense), net |
( |
) | ||||||
|
|
|
|
|||||
Loss before provision for income taxes |
( |
) | ( |
) | ||||
Provision for income taxes |
||||||||
|
|
|
|
|||||
Net loss and comprehensive loss |
( |
) | ( |
) | ||||
Net loss and comprehensive loss attributable to non-controlling interest |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Net loss and comprehensive loss attributable to Ginkgo Bioworks, Inc. stockholders |
$ | ( |
) | $ | ( |
) | ||
|
|
|
|
|||||
Net loss per share attributable to Ginkgo Bioworks, Inc. common stockholders, basic and diluted (1) |
$ | ( |
) | $ | ( |
) | ||
|
|
|
|
|||||
Weighted average common shares outstanding, basic and diluted (1) |
||||||||
|
|
|
|
(1) |
Retroactively restated for the reverse recapitalization as described in Note 1. |
Series B, C, D, E Convertible Preferred Stock |
Old Ginkgo Common Stock |
Common Stock |
||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||
Balance as of December 31, 2018 (as previously reported) |
$ |
$ |
— |
$ |
— |
|||||||||||||||||||
Retroactive application of the reverse recapitalization |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||
Balance as of December 31, 2018 |
||||||||||||||||||||||||
Exercise of stock options |
— |
— |
— |
— |
— |
|||||||||||||||||||
Issuance of Series E convertible preferred stock, net of issuance costs of $ |
— |
— |
— |
— |
||||||||||||||||||||
Recognition of beneficial conversion feature related to issuance of convertible promissory notes |
— |
— |
— |
— |
— |
— |
||||||||||||||||||
Reacquisition of beneficial conversion feature related to convertible promissory notes |
— |
— |
— |
— |
— |
— |
||||||||||||||||||
Conversion of convertible promissory notes into Series E convertible preferred stock |
— |
— |
— |
— |
||||||||||||||||||||
Vesting of restricted stock awards |
— |
— |
— |
— |
— |
|||||||||||||||||||
Repurchase of common stock |
— |
— |
— |
— |
— |
— |
||||||||||||||||||
Retirement of treasury stock |
— |
— |
— |
— |
( |
) |
( |
) | ||||||||||||||||
Issuance of warrants to purchase convertible preferred stock |
— |
— |
— |
— |
||||||||||||||||||||
Stock-based compensation expense |
— |
— |
— |
— |
— |
— |
||||||||||||||||||
Net loss and comprehensive loss |
— |
— |
— |
— |
— |
— |
||||||||||||||||||
Balance as of December 31, 2019 |
||||||||||||||||||||||||
Exercise of stock options |
— |
— |
— |
— |
— |
|||||||||||||||||||
Issuance of Series E convertible preferred stock, net of issuance costs of $ |
— |
— |
— |
— |
||||||||||||||||||||
Vesting of restricted stock awards |
— |
— |
— |
— |
— |
|||||||||||||||||||
Stock-based compensation expense |
— |
— |
— |
— |
— |
— |
||||||||||||||||||
Net loss and comprehensive loss |
— |
— |
— |
— |
— |
— |
||||||||||||||||||
Balance as of December 31, 2020 |
$ |
$ |
||||||||||||||||||||||
Treasury Stock |
||||||||||||||||||||||||
Shares |
Amount |
Additional Paid-In Capital |
Accumulated Deficit |
Non-Controlling Interest |
Total Stockholders’ Equity |
|||||||||||||||||||
Balance as of December 31, 2018 (as previously reported) |
( |
) |
$ |
( |
) |
$ |
$ |
( |
) |
$ |
$ |
|||||||||||||
Retroactive application of the reverse recapitalization |
( |
) |
( |
) |
— |
— |
— |
|||||||||||||||||
Balance as of December 31, 2018 |
( |
) |
( |
) |
( |
) |
||||||||||||||||||
Exercise of stock options |
— |
— |
— |
— |
||||||||||||||||||||
Issuance of Series E convertible preferred stock, net of issuance costs of $ |
— |
— |
— |
— |
||||||||||||||||||||
Recognition of beneficial conversion feature related to issuance of convertible promissory notes |
— |
— |
— |
— |
||||||||||||||||||||
Reacquisition of beneficial conversion feature related to convertible promissory notes |
— |
— |
( |
) |
— |
— |
( |
) | ||||||||||||||||
Conversion of convertible promissory notes into Series E convertible preferred stock |
— |
— |
— |
— |
||||||||||||||||||||
Vesting of restricted stock awards |
— |
— |
— |
— |
— |
— |
||||||||||||||||||
Repurchase of common stock |
( |
) |
( |
) |
— |
— |
— |
( |
) | |||||||||||||||
Retirement of treasury stock |
( |
) |
— |
|||||||||||||||||||||
Issuance of warrants to purchase convertible preferred stock |
— |
— |
— |
— |
||||||||||||||||||||
Stock-based compensation expense |
— |
— |
— |
— |
||||||||||||||||||||
Net loss and comprehensive loss |
— |
— |
— |
( |
) |
( |
) |
( |
) | |||||||||||||||
Balance as of December 31, 2019 |
— |
— |
( |
) |
||||||||||||||||||||
Exercise of stock options |
— |
— |
— |
— |
||||||||||||||||||||
Issuance of Series E convertible preferred stock, net of issuance costs of $ |
— |
— |
— |
— |
||||||||||||||||||||
Vesting of restricted stock awards |
— |
— |
— |
— |
— |
— |
||||||||||||||||||
Stock-based compensation expense |
— |
— |
— |
— |
||||||||||||||||||||
Net loss and comprehensive loss |
— |
— |
— |
( |
) |
( |
) |
( |
) | |||||||||||||||
Balance as of December 31, 2020 |
— |
— |
$ |
$ |
( |
) |
$ |
$ |
||||||||||||||||
Year Ended December 31, |
||||||||
2020 |
2019 |
|||||||
Cash flow from operating activities: |
||||||||
Net loss |
$ | ( |
) | $ | ( |
) | ||
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
Depreciation and amortization |
||||||||
Stock-based compensation |
||||||||
Loss attributable to equity method investments |
||||||||
Non-cash interest expense related to payments on lease financing obligations |
— | |||||||
Non-cash interest expense related to amortization of debt discount on convertible promissory notes |
— | |||||||
Gain on extinguishment of convertible promissory notes |
— | ( |
) | |||||
Loss attributable to investments |
||||||||
Accrued interest income on loan receivable |
— | ( |
) | |||||
Gain on termination of Glycosyn, LLC agreement |
— | ( |
) | |||||
Change in fair value of loans receivable |
( |
) | ||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable, net |
( |
) | ||||||
Accounts receivable, net from related parties (Note 2 0 ) |
( |
) | ( |
) | ||||
Prepaid expenses and other current assets |
( |
) | ( |
) | ||||
Inventory, net |
( |
) | — | |||||
Other non-current assets |
( |
) | ||||||
Accounts payable |
||||||||
Accrued expenses and other current liabilities |
||||||||
Deferred revenue, current and non-current (includes $( |
( |
) | ||||||
Deferred rent, non-current |
||||||||
Other non-current liabilities |
||||||||
|
|
|
|
|||||
Net cash used in operating activities |
( |
) | ( |
) | ||||
Cash flow from investing activities: |
||||||||
Purchases of property and equipment |
( |
) | ( |
) | ||||
Purchase of loan receivable from Access Bio, Inc. |
( |
) | — | |||||
Issuance of loans receivable |
( |
) | ( |
) | ||||
Cash paid for investment in Synlogic, Inc. |
— | ( |
) | |||||
Proceeds from loans receivable |
— | |||||||
|
|
|
|
|||||
Net cash used in investing activities |
( |
) | ( |
) | ||||
Cash flow from financing activities: |
||||||||
Proceeds from exercise of stock options |
||||||||
Repurchase of common stock |
( |
) | ||||||
Principal payment on capital lease obligations |
( |
) | ( |
) | ||||
Proceeds from lease financing obligations |
— | |||||||
Principal payment on lease financing obligations |
( |
) | ( |
) | ||||
Proceeds from issuance of convertible promissory notes, net of issuance costs |
— | |||||||
Proceeds from issuance of Series E convertible preferred stock, net of issuance costs |
||||||||
|
|
|
|
|||||
Net cash provided by financing activities |
||||||||
Net increase (decrease) in cash, cash equivalents and restricted cash |
( |
) |
Year Ended December 31, |
||||||||
2020 |
2019 |
|||||||
Cash, cash equivalents and restricted cash, beginning of period |
$ | $ | ||||||
|
|
|
|
|||||
Cash, cash equivalents and restricted cash, end of period |
$ | $ | ||||||
|
|
|
|
|||||
Supplemental disclosure of cash flow information: |
||||||||
Cash paid for interest |
$ | $ | ||||||
Cash paid for income taxes |
$ | — | $ | |||||
Supplemental disclosure of non-cash investing and financing activities: |
||||||||
Purchases of equipment through capital leases |
$ | — | $ | |||||
Purchases of property and equipment included in accounts payable and accrued expenses |
$ | $ | ||||||
Conversion of convertible promissory notes into Series E convertible preferred stock |
$ | — | $ | |||||
Series E convertible preferred stock issuance costs included in accrued expenses |
$ | — | $ | |||||
Issuance of loan receivable upon amendment of Glycosyn, LLC agreement |
$ | — | $ | |||||
Allonnia, LLC equity interest received for intellectual property |
$ | — | $ | |||||
Loan receivable received as consideration under customer arrangement |
$ | $ | — |
As of December 31, |
||||||||
2020 |
2019 |
|||||||
Cash and cash equivalents |
$ | $ | ||||||
Restricted cash |
||||||||
|
|
|
|
|||||
Total cash, cash equivalents and restricted cash |
$ | $ | ||||||
|
|
|
|
Estimated Useful Life | ||
Computer equipment and software |
||
Furniture and fixtures |
||
Lab equipment |
||
Facilities |
||
Leasehold improvements |
remaining lease term |
• |
Level 1- Quoted prices (unadjusted) in active markets for identical assets or liabilities; |
• |
Level 2- Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and |
• |
Level 3- Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing. |
As of December 31, 2020 |
||||||||||||||||
Total |
Level 1 |
Level 2 |
Level 3 |
|||||||||||||
Assets: |
||||||||||||||||
Money market funds, included in cash and cash equivalents |
$ | $ | $ | $ | ||||||||||||
Synlogic, Inc. common stock, included in equity method investments |
||||||||||||||||
Synlogic, Inc. warrant, included in investments |
||||||||||||||||
Loans receivable, included in prepaid expenses and other current assets |
||||||||||||||||
Loans receivable, net of current portion |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
As of December 31, 2019 |
||||||||||||||||
Total |
Level 1 |
Level 2 |
Level 3 |
|||||||||||||
Assets: |
||||||||||||||||
Money market funds, included in cash and cash equivalents |
$ | $ | $ | $ | ||||||||||||
Synlogic, Inc. common stock, included in equity method investments |
||||||||||||||||
Synlogic, Inc. warrant, included in investments |
||||||||||||||||
Loan receivable, included in prepaid expenses and other current assets |
||||||||||||||||
Loan receivable, net of current portion |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
Loans Receivable |
||||
Balance as of December 31, 2018 |
$ | |||
Issuance of loan receivable |
||||
Change in fair value |
( |
) | ||
|
|
|||
Balance as of December 31, 2019 |
$ | |||
|
|
|||
Purchase of loan receivable |
||||
Issuance of loans receivable |
||||
Proceeds from loans receivable |
( |
) | ||
Change in fair value |
||||
|
|
|||
Balance as of December 31, 2020 |
$ | |||
|
|
As of December 31, |
||||||||
2020 |
2019 |
|||||||
Prepaid expenses |
$ | $ | ||||||
Prepaid inventory |
||||||||
Loans receivable |
||||||||
Other current assets |
||||||||
|
|
|
|
|||||
Prepaid expenses and other current assets |
$ | $ | ||||||
|
|
|
|
As of December 31, |
||||||||
2020 |
2019 |
|||||||
Finished goods |
$ | $ | ||||||
Less: Inventory reserve |
( |
) | ||||||
|
|
|
|
|||||
Inventory, net |
$ | $ | ||||||
|
|
|
|
As of December 31, |
||||||||
2020 |
2019 |
|||||||
Facilities |
$ | $ | ||||||
Furniture and fixtures |
||||||||
Lab equipment |
||||||||
Computer equipment and software |
||||||||
Leasehold improvements |
||||||||
Construction in progress |
||||||||
|
|
|
|
|||||
Total property and equipment |
||||||||
Less: Accumulated depreciation |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Property and equipment, net |
$ | $ | ||||||
|
|
|
|
As of December 31, |
||||||||
2020 |
2019 |
|||||||
Investments: |
||||||||
Genomatica, Inc. preferred stock |
$ | $ | ||||||
Synlogic, Inc. warrant |
||||||||
|
|
|
|
|||||
Total |
$ | $ | ||||||
|
|
|
|
|||||
Equity method investments: |
||||||||
Joyn Bio, LLC |
$ | $ | ||||||
Synlogic, Inc. |
||||||||
|
|
|
|
|||||
Total |
$ | $ | ||||||
|
|
|
|
Year Ended December 31, |
||||||||
2020 |
2019 |
|||||||
Loss on investments: |
||||||||
Synlogic, Inc. warrant |
$ | ( |
) | $ | ( |
) | ||
|
|
|
|
|||||
Total |
$ | ( |
) | $ | ( |
) | ||
|
|
|
|
|||||
Loss on equity method investments: |
||||||||
Joyn Bio, LLC |
$ | ( |
) | $ | ( |
) | ||
Glycosyn, LLC |
( |
) | ||||||
Synlogic, Inc. |
( |
) | ( |
) | ||||
Allonnia, LLC |
( |
) | ||||||
|
|
|
|
|||||
Total |
$ | ( |
) | $ | ( |
) | ||
|
|
|
|
As of December 31, |
||||||||
2020 |
2019 |
|||||||
Assets |
$ | $ | ||||||
Liabilities |
$ | $ |
Year Ended December 31, |
||||||||
2020 |
2019 |
|||||||
Revenue |
$ | $ | ||||||
Total operating expenses |
$ | ( |
) | $ | ( |
) | ||
Loss from operations |
$ | ( |
) | $ | ( |
) | ||
Net loss |
$ | ( |
) | $ | ( |
) |
Gross Carrying Value |
Accumulated Amortization |
Net |
||||||||||
Balances as of December 31, 2020 |
||||||||||||
Acquired technology |
$ | $ | ( |
) | $ | |||||||
Balances as of December 31, 2019 |
||||||||||||
Acquired technology |
$ | $ | ( |
) | $ |
10. |
Accrued Expenses and Other Current Liabilities |
As of December 31, |
||||||||
2020 |
2019 |
|||||||
Accrued compensation and benefits |
$ | $ | ||||||
Accrued professional fees |
||||||||
Accrued financing costs |
||||||||
Capital lease obligation |
||||||||
Accrued property and equipment |
||||||||
Accrued lab supplies |
||||||||
Accrued external research and development expenses |
||||||||
Other current liabilities |
||||||||
|
|
|
|
|||||
Accrued expenses and other current liabilities |
$ | $ | ||||||
|
|
|
|
Years Ending December 31, |
Minimum Lease Payments |
|||
2021 |
$ | |||
2022 |
||||
2023 |
||||
2024 |
||||
2025 |
||||
Thereafter |
||||
|
|
|||
Total |
$ | |||
|
|
Years Ending December 31, |
Minimum Lease Payments |
|||
2021 |
$ | |||
2022 |
||||
2023 |
||||
2024 |
||||
2025 |
||||
Thereafter |
||||
|
|
|||
Total noncancelable payments |
$ | |||
Less: Imputed interest expense |
( |
) | ||
|
|
|||
Present value of future minimum lease payments |
$ | |||
|
|
Contract Years |
Minimum Purchase Commitment |
|||
October 1, 2019 - September 30, 2020 |
$ | |||
October 1, 2020 - March 31, 2022 |
||||
April 1, 2022 - March 31, 2023 |
||||
April 1, 2023 - March 31, 2024 |
||||
April 1, 2024 - March 31, 2025 |
||||
Thereafter |
||||
|
|
|||
Total |
$ | |||
|
|
12. |
Convertible Promissory Notes |
13. |
Stockholders’ Equity |
As of December 31, |
||||||||
2020 |
2019 |
|||||||
Shares reserved for warrants to purchase common stock |
||||||||
Shares reserved for exercises of outstanding stock options under the 2008 Stock Incentive Plan |
||||||||
Shares reserved for vesting of restricted stock units under the 2014 Stock Incentive Plan |
||||||||
Shares reserved for issuances under the 2014 Stock Incentive Plan |
||||||||
|
|
|
|
|||||
Total common stock reserved for future issuances |
||||||||
|
|
|
|
14. |
Stock-Based Compensation |
Number of Shares |
Weighted Average Exercise Price per Share |
Weighted Average Remaining Contractual Term |
Aggregate Intrinsic Value(1) |
|||||||||||||
(in years) | (in thousands) | |||||||||||||||
Outstanding as of December 31, 2019 |
$ | $ | ||||||||||||||
Exercised |
( |
) | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Outstanding as of December 31, 2020 |
$ | $ | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Exercisable as of December 31, 2020 |
$ | $ | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
(1) The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the common stock for those stock options that had exercise prices lower than the estimated fair value of the common stock as of December 31, 2020 and 2019. | |
Number of Shares |
Weighted Average Grant Date Fair Value |
|||||||
Nonvested as of December 31, 2019 |
$ | |||||||
Granted |
||||||||
Forfeited |
( |
) | ||||||
|
|
|
|
|||||
Nonvested as of December 31, 2020 |
$ | |||||||
|
|
|
|
Number of Shares |
Weighted Average Grant Date Fair Value |
|||||||
Nonvested as of December 31, 2019 |
$ | |||||||
Vested |
( |
) | ||||||
|
|
|
|
|||||
Nonvested as of December 31, 2020 |
$ | |||||||
|
|
|
|
Years Ended December 31, |
||||||||
2020 |
2019 |
|||||||
Research and development |
$ | $ | ||||||
General and administrative |
||||||||
|
|
|
|
|||||
Total |
$ | $ | ||||||
|
|
|
|
Year Ended December 31, |
||||||||
2020 |
2019 |
|||||||
Food and nutrition |
% | % | ||||||
Industrial and environmental |
% | % | ||||||
Agriculture |
% | % | ||||||
Consumer and technology |
% | % | ||||||
Other |
% | % | ||||||
|
|
|
|
|||||
Total |
% | % | ||||||
|
|
|
|
Year Ended December 31, |
||||||||
2020 |
2019 |
|||||||
North America |
% | % | ||||||
Rest of world |
% | % | ||||||
|
|
|
|
|||||
Total |
% | % | ||||||
|
|
|
|
Years Ended December 31, |
||||||||
2020 |
2019 |
|||||||
Domestic |
$ | ( |
) | $ | ( |
) | ||
Foreign |
||||||||
|
|
|
|
|||||
Total |
$ | ( |
) | $ | ( |
) | ||
|
|
|
|
Years Ended December 31, |
||||||||
2020 |
2019 |
|||||||
Income tax expense: |
||||||||
Current federal income tax |
$ | $ | ||||||
Current state income tax |
||||||||
Deferred federal income tax |
||||||||
Deferred state income tax |
||||||||
|
|
|
|
|||||
Income tax expense |
$ | $ | ||||||
|
|
|
|
Years Ended December 31, |
||||||||
2020 |
2019 |
|||||||
Tax expense computed at the federal statutory rate |
% | % | ||||||
State taxes |
% | % | ||||||
Change in valuation allowance |
( |
%) | ( |
%) | ||||
Equity investments |
( |
%) | ( |
%) | ||||
Tax credits |
% | % | ||||||
Non-deductible expenses |
( |
%) | ( |
%) | ||||
Other expenses |
% | % | ||||||
|
|
|
|
|||||
Total income tax expense |
( |
%) | % | |||||
|
|
|
|
Years Ended December 31, |
||||||||
2020 |
2019 |
|||||||
Deferred tax assets: |
||||||||
Net operating loss carryforwards |
$ | $ | ||||||
Tax credit carryforwards |
||||||||
Accrued expenses |
||||||||
Deferred revenue |
||||||||
Amortizable intangibles |
||||||||
Tenant allowance |
||||||||
|
|
|
|
|||||
Deferred tax assets before valuation allowance |
||||||||
Valuation allowance |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Deferred tax assets |
||||||||
Deferred tax liabilities: |
||||||||
Equity-based compensation |
( |
) | ||||||
Property and equipment |
( |
) | ( |
) | ||||
Basis differences |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Deferred tax liabilities |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Net deferred taxes |
$ | ( |
) | $ | ||||
|
|
|
|
Beginning of Period |
Additions |
Reductions/ Charges |
End of Period |
|||||||||||||
Deferred tax assets valuation allowance: |
||||||||||||||||
Year Ended December 31, 2020 |
$ | $ | $ | $ | ||||||||||||
Year Ended December 31, 2019 |
$ | $ | $ | $ |
Year Ended December 31, |
||||||||
2020 |
2019 |
|||||||
Warrants to purchase common stock |
||||||||
Outstanding stock options |
||||||||
Unvested RSUs |
||||||||
Unvested RSAs |
2 0 . |
Related Parties |
Joyn |
Motif |
Genomatica |
Allonnia |
Synlogic |
Total |
|||||||||||||||||||
Balances as of December 31, 2020 |
||||||||||||||||||||||||
Accounts receivable, net |
$ | $ | $ | $ | $ | |
$ |
|||||||||||||||||
Prepaid expenses and other current assets |
$ | $ | $ | $ | $ | $ |
||||||||||||||||||
Deferred revenue, current and non-current |
$ | $ | $ | $ | $ | $ |
||||||||||||||||||
Balances as of December 31, 2019 |
||||||||||||||||||||||||
Accounts receivable, net |
$ | $ | $ | $ | $ | $ |
||||||||||||||||||
Deferred revenue, current and non-current |
$ | $ | $ | $ | $ | $ |
Joyn |
Motif |
Genomatica |
Allonnia |
Synlogic |
Glycosyn |
Total |
||||||||||||||||||||||
For the Year Ended December 31, 2020 |
||||||||||||||||||||||||||||
Foundry revenue |
$ | $ | $ | $ | $ | $ | $ |
|||||||||||||||||||||
Other income, net |
$ | $ | $ | $ | $ | |
$ | $ |
||||||||||||||||||||
For the Year Ended December 31, 2019 |
||||||||||||||||||||||||||||
Foundry revenue |
$ | $ | $ | $ | $ | $ | $ |
|||||||||||||||||||||
Interest income |
$ | $ | $ | $ | $ | $ | $ |
|||||||||||||||||||||
Other income, net |
$ | $ | $ | $ | $ | $ | $ |
Joyn |
Motif |
Genomatica |
Allonnia |
Synlogic |
Glycosyn |
Total |
||||||||||||||||||||||
For the Year Ended December 31, 2020 |
||||||||||||||||||||||||||||
Accounts receivable, net |
$ | $ | $ | ( |
) | $ | ( |
) | $ | $ | $ |
( |
) | |||||||||||||||
Prepaid expenses and other current assets |
$ | ( |
) | $ | ( |
) | $ | $ | ( |
) | $ | $ | $ |
( |
) | |||||||||||||
Deferred revenue, current and non-current |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | $ | ( |
) | $ | $ |
( |
) | |||||||||||
For the Year Ended December 31, 2019 |
||||||||||||||||||||||||||||
Accounts receivable, net |
$ | ( |
) | $ | ( |
) | $ | $ | $ | |
$ | ( |
) | $ |
( |
) | ||||||||||||
Deferred revenue, current and non-current |
$ | $ | $ | ( |
) | $ | $ | $ | ( |
) | $ |